Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited (PAR.AX) Financial Performance & Income Statement Overview
Review Paradigm Biopharmaceuticals Limited (PAR.AX) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Paradigm Biopharmaceuticals Limited (PAR.AX) Income Statement & Financial Overview
Review Paradigm Biopharmaceuticals Limited PAR.AX income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $16700.00 | $65800.00 | $0.00 | $42050.00 |
| Cost of Revenue | $18715.00 | $82327.00 | $73397.00 | $88222.00 |
| Gross Profit | -$2015.00 | -$8988.00 | -$73397.00 | -$46172.00 |
| Gross Profit Ratio | -$0.12 | -$0.14 | $0.00 | -$1.10 |
| R&D Expenses | $3.99M | $11.96M | $46.37M | $24.95M |
| SG&A Expenses | $2.36M | $3.00M | $3.45M | $1.92M |
| Operating Expenses | $6.35M | $14.96M | $49.82M | $26.87M |
| Total Costs & Expenses | $6.36M | $14.97M | $49.89M | $26.96M |
| Interest Income | $0.00 | $195037.00 | $211977.00 | $1.08M |
| Interest Expense | $0.00 | $7891.00 | $6479.00 | $7662.00 |
| Depreciation & Amortization | $71472.00 | $73339.00 | $73397.00 | $76756.00 |
| EBITDA | -$6.28M | -$14.89M | -$50.07M | -$27.25M |
| EBITDA Ratio | -$375.82 | -$226.32 | $0.00 | -$638.36 |
| Operating Income | -$6.35M | -$14.97M | -$49.89M | -$26.92M |
| Operating Income Ratio | -$380.10 | -$227.45 | $0.00 | -$640.19 |
| Other Income/Expenses (Net) | $92624.00 | $284735.00 | -$126000.00 | $611090.00 |
| Income Before Tax | -$6.26M | -$14.68M | -$50.02M | -$26.31M |
| Income Before Tax Ratio | -$374.55 | -$223.12 | $0.00 | -$625.66 |
| Income Tax Expense | -$330984.00 | -$4.99M | -$1.06M | -$6.27M |
| Net Income | -$5.92M | -$9.70M | -$48.96M | -$20.04M |
| Net Income Ratio | -$354.73 | -$147.34 | $0.00 | -$476.64 |
| EPS | -$0.02 | -$0.03 | -$0.16 | -$0.07 |
| Diluted EPS | -$0.02 | -$0.03 | -$0.16 | -$0.07 |
| Weighted Avg Shares Outstanding | $354.06M | $286.60M | $299.79M | $289.68M |
| Weighted Avg Shares Outstanding (Diluted) | $354.05M | $286.78M | $299.79M | $289.68M |
The company's financials show resilient growth, with revenue advancing from $42050.00 in Q4 2023 to $16700.00 in Q2 2025. Gross profit remained healthy with margins at -12% in Q2 2025 compared to -110% in Q4 2023. Operating income hit -$6.35M last quarter, sustaining a consistent -38010% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$6.28M. Net income rose to -$5.92M, while earnings per share reached -$0.02. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan